Latest Breaking News On - Patients through promoting competition act - Page 1 : comparemela.com

US legislative update: takeaways for European pharma

Keith A Zullow and Jenny J Zhang examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma.

New yorkUnited statesJennyj zhangKeitha zullowSupreme courtHuman servicesDrug administrationUs congressUs federal trade commissionGoodwin procterInflation reduction actCitizen petitionCitizen petitionsSenate billEnsuring timely accessGenerics act

Biosimilars 2021 Year in Review | Fish & Richardson

2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology.

New yorkUnited statesDistrict of columbiaSamsung bioepis merckSeecertain adalimumabEli lillyAbbvie humiraSanofi aventis deutschland gmbBiosimilar blasPauld tonkoViatris semgleeAmgen riabniImmunex enbrelCelltrion tevaFresenius kabiAmgen allergan

Big Pharma mergers and acquisitions destroy industry innovation and harm patients

Big Pharma mergers and acquisitions destroy industry innovation and harm patients
naturalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from naturalnews.com Daily Mail and Mail on Sunday newspapers.

United statesElijahe cummingsLaurent galibertKatie porterInstitute for competition economicsBig pharmaNatural newsHow big pharma takeovers destroy innovationCompetition economicsHarvard business reviewFederal trade commissionLower drug costs now actPreserve accessAffordable genericsBiosimilars actAffordable prescription

How Big Pharma Pursues Killer Profits at Americans Expense — Strategic Culture

February 2, 2021 © Photo: Wikimedia “Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends,” the report says, “all while swallowing smaller companies, thus making the marketplace far less competitive.” By Brett WILKINS Rep. Katie Porter (D-CA) on Friday published a damning report revealing the devastating effects of Big Pharma mergers and acquisitions on U.S. healthcare, and recommending steps Congress should take to enact “comprehensive, urgent reform” of an integral part of a broken healthcare system. The report, entitled “Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients,” begins by noting that “in just 10 years, the number of large, international pharmaceutical companies decreased six-fold, from 60 to only 10.”

United statesDonald trumpKatie porter repkatieporterElijahe cummingsKatie porterBig pharmaHow big pharma takeovers destroy innovationHarm patientsWall streetFederal trade commissionLower drug costs now actPreserve accessAffordable genericsBiosimilars actAffordable prescriptionPatients through promoting competition act